{
    "Trade/Device Name(s)": [
        "Synermed Opiate Enzyme Immunoassay"
    ],
    "Submitter Information": "Infrared Laboratory Systems, LLC (dba Synermed)",
    "510(k) Number": "K172416",
    "Predicate Device Reference 510(k) Number(s)": [
        "K110298"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "April 19, 2018",
    "Summary Letter Received Date": "March 5, 2018",
    "Submission Date": "August 3, 2017",
    "Regulation Number(s)": [
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Morphine",
        "Opiates"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Synermed IR-500",
        "Hitachi 717"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Synermed Opiate Enzyme Immunoassay for qualitative and semi-quantitative determination of opiates in urine using enzyme immunoassay methodology.",
    "Indications for Use Summary": "Qualitative and semi-quantitative determination of opiates in human urine at 300 ng/mL cutoff, calibrated against morphine, for use with automated clinical chemistry analyzers; intended for prescription professional use only and provides a preliminary result requiring confirmation with a more specific analytical method such as GC/MS or LC/MS.",
    "fda_folder": "Toxicology"
}